ALZpath and Siemens Healthineers have signed a licensing agreement to accelerate global access to blood-based Alzheimer’s disease diagnostic testing. 🔗Read the full press release: alzpath.bio/alzpath-and-...

Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions. 🔗See the full list of posters & presentations: alzpath.bio/wp-content/u...

📢#CTAD2025 is just two weeks away! As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today 🔗Explore now: www.alzpath.bio Attending CTAD? Let’s connect: [email protected]

How reliable are blood-based pTau217 tests compared to PET or CSF? Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis. 🔗Learn more: alzpath.bio/faqs

ALZpath’s proprietary #pTau217 antibody has been named Diagnostics Innovation of the Year by the 2025 #BioTechBreakthroughAwards — recognizing its impact in advancing earlier, more accessible #AlzheimersDisease detection. 🔗Read more: alzpath.bio/alzpath-prop...

In a new article from PM Live, ALZpath Distinguished Scientific Advisor Dr. Henrik Zetterberg shares three pillars advancing Alzheimer’s blood testing - sensitivity, accessibility, and education - powered by biomarkers like pTau217. Read now: pmlive.com/intelligence... #ptau217 #alzheimers

We’re headed to #CTAD2025 in San Diego! ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers. Attending? Let’s connect — reach out at [email protected] to schedule a meeting. #AlzheimersDisease #Research

The FDA approved LEQEMBI® IQLIK™, a new at-home injectable that targets amyloid to help slow early #Alzheimers. Weekly at-home care removes infusion visits and improves access. #EarlyDetection is key to ensuring patients can benefit most. 📖Read the full article: time.com/7314266/alzh...

#pTau217 could change how Alzheimer’s is diagnosed. BioWorld News explores its potential for earlier detection and treatment monitoring, with insight from ALZpath VP of R&D Lee Honigberg, PhD. Read the full article: www.bioworld.com/articles/724... #AlzheimersDisease #BloodBiomarkers #Diagnosis

💜 Yesterday was #WorldAlzheimersDay, honoring the millions living with Alzheimer’s disease and the families who support them. At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything. 🔗Learn more at: www.alzpath.bio

📢 Today, Alzheimer’s Disease International released the World Alzheimer Report 2025 on rehabilitation to support life after diagnosis. Read the full report: www.alzint.org/resource/wor... #WorldAlzheimersReport #AlzheimersDisease

🧠 Which plasma biomarker best detects Alzheimer’s disease? A head-to-head study (Alzheimer’s & Dementia, Jan 2025) compared 22 biomarkers in a memory clinic. The results: #pTau217 showed the highest accuracy and strongest correlation with CSF. 📄 pmc.ncbi.nlm.nih.gov/articles/PMC...

In a new executive interview with Drug Development & Delivery, our Chief Business Officer, Jacob Hunter shares how ALZpath’s #pTau217 antibody is enabling earlier, scalable detection of #AlzheimersDisease. 🔗Learn more in the full interview: drug-dev.com/executive-in... #Antibody #ALZpath

September is #WorldAlzheimersMonth, a global call to raise awareness and take action. Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers. At ALZpath, we’re working to change that. Learn more at alzpath.bio. #AskAboutAlzheimers

At this year’s #AAIC25, ALZpath CEO Mike Banville joined NeurologyLive to discuss how the ALZpath proprietary #pTau217 antibody is powering blood-based testing to enable earlier, scalable Alzheimer’s disease detection. 🧠💜 📌Watch the full interview here: www.neurologylive.com/view/expandi...

What a week at #AAIC2025 🧠 ALZpath was proud to connect with global leaders in Alzheimer’s disease care and our Advisory Board. @alzassociation.bsky.social released new Blood-Based Biomarker Guidelines—congrats to Dr. Henrik Zetterberg, our Distinguished Scientific Advisor, for his contribution.

A pivotal step for Alzheimer’s disease care: The @alzassociation.bsky.social has released its first guideline on blood-based biomarker testing. We're proud to see growing validation of blood-based tests, including those powered by ALZpath’s #pTau217 antibody, for earlier, more accurate diagnosis.

ALZpath Wins 2025 Edison Bronze Award for Innovative Alzheimer's Testing Solution#USA#Carlsbad#ALZpath#Edison_Award#pTau217_Antibody

ALZpath is headed to Toronto for #AAIC25! If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect. Email [email protected] to set up a meeting. #AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath

ALZpath Recognized as One of the World's Top Innovators by Fast Company in 2025#USA#Alzheimer's_Disease#Carlsbad#Fast_Company#ALZpath